ACEI/ARB在房颤一级预防中的可能作用
被引量：2
摘要
肾素-血管紧张素-醛固酮系统(RAAS)在心房颤动的发生中扮演了重要角色,这为RAAS系统抑制剂预防房颤提供了理论依据。文章将ACEI/ARB预防房颤的可能作用机制,以及在房颤治疗中的临床应用作一综述。
出处
《临床和实验医学杂志》
2012年第23期1900-1902,共3页
Journal of Clinical and Experimental Medicine
参考文献19
-
1Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long - standing per- sistent atrial fibrillation: Results of a prospective and controlled study [J]. Eur Heart J, 2003,24(23) :2090 -2098.
-
2Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation [ J ]. Circulation, 2000.101 (22) :2612 - 2617.
-
3Kolb C, Numberger S, Ndrepepa G, et al. Modes of initiation of paroxysmal atrial fibrillation from analysis of spontaneously occurring episodes using a 12 -lead Hoher monitoring system[J]. Am J Cardiol, 2001,88(8) :853-857.
-
4Goette A, Hoffmanns P, Enayati W, et al. Effect of successful electri- cal cardioversion on serum aldosterone in patients with persistent atrial fibrillation[ J]. Am J Cardiol, 2001, 88 (8) :906 - 909.
-
5Goette A, Staack T, Rocken C, et al. Increased expression of extracel- lular signal - regulated kinase and angiotensin - converting enzyme in human atria during atrial fibrillation[ J]. J Am Coil Cardiol, 2000,35 (6) :1669 - 1677.
-
6LAllier PL, Duehanne A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occur- fence (ff atrial fibrillation[ J]. J Am Coil Cardiol, 2004,44( 1 ) :159 - 154.
-
7Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new - onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hyper- tension(LIFE) study[ J]. J Am Coil Cardiol, 2005,45 (5) :712 - 719.
-
8Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of anti - hypertensive treatment on clinical e- vents in the VALUE trial[ J ]. Lancet, 2004,363 (9426) :2049 - 2051.
-
9Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by wayof abrogation of the renin - angiotensin system : A systematic review and meta - analysis [ J ]. Am J Therapeutics, 2008, 15 ( 1 ) :36 - 43.
-
10Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the inci- dence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials [ J ]. Circulation, 2003,107 ( 23 ) : 2926 - 2931.
同被引文献32
-
1张标,曾晓荣,杨艳,刘智飞,张瑜.心房颤动患者心房肌乙酰胆碱敏感钾通道基因表达变化的研究[J].泸州医学院学报,2004,27(3):192-195. 被引量：2
-
2周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量：1399
-
3段徐,凌峰.炎症与心房颤动的关系研究进展[J].心脑血管病防治,2006,6(1):52-54. 被引量：1
-
4吴凯,何泮,廖蔚茜.化痰安神熄风法对原发性高血压疗效及C-反应蛋白水平的影响[J].广东医学,2007,28(8):1350-1351. 被引量：3
-
5魏玲,刘斌,李丽娟,卢国良,侯宗柳,刘绍华,张亚林,张筱军.血管紧张素转换酶基因多态性与房颤心肌纤维化的相关性研究[J].西南国防医药,2007,17(6):704-706. 被引量：2
-
6Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mech- anisms of atrial fibrillation : a translational appraisal [ J ]. Physiol Rev,2011,91 ( 1 ) :265 - 325.
-
7Guo P, Wu C, Masaki T, et al. Subdose of fasudil suppresses myo- cardial fibrosis in aldosterone-salt-treated uninephrectomized rats [J]. Pharmazie,2011,66(9) :716 -719.
-
8Lallier PL, Ducharme A, Keller PF, et al.' Angiotensin-converting en- zyme inhibition in hypertensive patients is associated with a reduc- tion in the occurrence of atrial fibrillation[ J]. J Am Coil Cardiol, 2004,44( 1 ) :159 - 164.
-
9Dabrowski R, Borowiec A,Smolis-Bak E,et al. Effect combined spi- ronolactone - 13 blocker-enalapril treatment on occurrence of symp- tomatic atrial fibrillation episodes in patients with a history of parox- ysmal atrial fibrillation ( SPIR - AF study) [ J ]. Am J Cardiol, 2010,106(11) :1609 - 1614.
-
10Bddt A,Scholl A, Garbade J. ACE - inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibril- lation [ J ]. Basic Res Cardio1,2006,101 ( 3 ) : 261 - 267.
二级引证文献5
-
1许键,何燕,罗蓓蓓.心脏炎症反应与心房颤动射频消融术后再发的研究(综述)[J].安徽卫生职业技术学院学报,2016,15(3):29-30. 被引量：3
-
2沈斌,李香伟,温昭科,林辉.心脏不停跳瓣膜置换同期双极射频消融对后并行循环的影响[J].中国临床新医学,2016,9(7):559-563. 被引量：1
-
3罗俏.非洛地平结合半夏白术天麻汤用于老年原发性高血压治疗的效果分析[J].黑龙江医药,2017,30(6):1246-1248. 被引量：6
-
4罗俊.半夏白术天麻汤配合耳石复位法对良性阵发性位置性眩晕的疗效分析[J].中国医药指南,2018,16(16):199-200. 被引量：4
-
5邵鑫,王彦.中医治疗阵发性心房颤动研究进展[J].河北中医,2023,45(7):1214-1217. 被引量：2
-
1常新荣.卡托普利、倍他乐克联用螺内酯治疗慢性充血性心力衰竭90例[J].陕西医学杂志,2005,34(6):732-733. 被引量：1
-
2李小华,陆士娟,林德洪.曲美他嗪、螺内酯联合治疗充血性心力衰竭的临床观察[J].中国热带医学,2007,7(4):554-555. 被引量：1
-
3钟文,李迪.阿托伐他汀治疗慢性心力衰竭的临床疗效观察[J].医学信息,2012,25(10):124-125. 被引量：2
-
4叶炯标.培哚普利与卡托普利治疗原发性高血压的临床效果比较[J].中国社区医师（医学专业）,2010,12(14):39-39. 被引量：4
-
5张敏,林善锬.治疗糖尿病肾病血管紧张素Ⅱ受体阻滞剂的10大优点[J].糖尿病新世界,2005(4):14-15.
-
6张卫国.低分子肝素治疗不稳定型心绞痛临床观察[J].临床和实验医学杂志,2008,7(11):90-90. 被引量：1
-
7赵华月.血管紧张素转换酶抑制剂在心血管病中的应用[J].医药导报,1999,18(1):4-5.
-
8吴沃栋,沈彦荣,陈次滨,陈希明.血管紧张素转换酶抑制剂在急性心肌梗塞早期的应用[J].中国危重病急救医学,1996,8(2):91-93.
-
9周颖,刘雨晶,陈雷.血管紧张素转换酶抑制剂治疗充血性心力衰竭的临床观察[J].黑龙江医学,2003,27(8):603-603.
-
10张柏源,周健,齐玉芹,张平.卡托普利治疗糖尿病肾病72例效果分析[J].现代康复,1999,3(3):370-371.
